Vertex Pharmaceuticals Inc
Company Profile
Business description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Contact
50 Northern Avenue
BostonMA02210
USAT: +1 617 341-6100
E: investorinfo@vrtx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6,100
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,622.10 | 92.30 | 1.08% |
| CAC 40 | 7,853.47 | 16.68 | 0.21% |
| DAX 40 | 23,695.59 | 168.58 | 0.72% |
| Dow JONES (US) | 42,322.75 | 271.69 | 0.65% |
| FTSE 100 | 8,633.75 | 48.74 | 0.57% |
| HKSE | 23,453.16 | 187.49 | -0.79% |
| NASDAQ | 19,112.32 | 34.49 | -0.18% |
| Nikkei 225 | 37,623.35 | 132.16 | -0.35% |
| NZX 50 Index | 12,813.56 | 67.26 | -0.52% |
| S&P 500 | 5,916.93 | 24.35 | 0.41% |
| S&P/ASX 200 | 8,391.10 | 93.60 | 1.13% |
| SSE Composite Index | 3,380.82 | 23.13 | -0.68% |